Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC)
Authors
Vogel, A.Chen, L. T.
He, A. R.
Kim, J. W.
Chen, M. H.
McNamara, Mairead G
Shimizu, S.
Gillmore, R.
Rey, F.
Kim, H.
Xiong, J.
Makowsky, M.
Rokutanda, N.
Cohen, G.
Oh, D. Y.
Affiliation
Hannover Medical School, Hannover, GermanyIssue Date
2022
Metadata
Show full item recordCitation
Vogel A, Chen LT, He AR, Kim JW, Chen MH, McNamara MG, et al. Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301241.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.4075Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.4075Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.4075